SLDB
Solid Biosciences Inc.
Solid Biosciences Inc. (SLDB) is currently in an uptrend, trading above both the 50-day and 200-day moving averages. RSI is at 48.9, with 3/3 trend checks passing.
SLDB with MA50 and MA200
Key levels & signals
SLDB valuation multiples (TTM)
SLDB analyst consensus
Solid Biosciences Inc. (SLDB) is still trading in a constructive trend overall. The latest available price is $9.18, and 3 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 13.5% and above the 200-day moving average by 36.9%.
SLDB currently has an RSI reading of 48.9, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.
For traders reviewing SLDB next, the key question is whether the trend still looks healthy or whether price has started to outrun itself. A strong uptrend can stay strong, but entries often become more difficult when price is already extended, so many traders will watch for pullbacks, support reactions, or fresh bases rather than chasing strength blindly.
About Solid Biosciences Inc.
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
SLDB shares outstanding over time
Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.
Learn the indicators behind this page
More stock opportunities
Common questions about SLDB
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.